β‐amyloid protein, tau protein, structural or functional MRI, and even fluorodeoxyglucose positron emission tomography computed tomography (FDG‐PET) and Pittsburgh B amyloid positron emission tomography (PIB‐PET) in CSF have been reported to confirm the existence of AD‐related pathological changes in SCD (Braak et al., 2011; Kapasi et al., 2017; Thomas et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.